Konstantin Dobrenkov

Medicine · Health Sciences

16h-index1.1kcitations53works0.52yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(19), Immunotherapy and Immune Responses(17), CAR-T cell therapy research(9), Neuroblastoma Research and Treatments(8), Virus-based gene therapy research(7)

Publications53 total

The Dose and Dosing Schedule Selection for an Investigational Immuno-Oncology Drug Based on a Pharmacokinetics and Pharmacodynamic Model of Tolerance
2026Open Access
Abstract 4364: Preclinical pharmacokinetics and pharmacodynamics of MK-4464, a novel NK cell engager targeting CEACAM5
Cancer Research·2025· 1 cited
Abstract CT095: Phase 1 evaluation of triple therapy with boserolimab (anti-CD27 agonist), pembrolizumab, and chemotherapy in patients with triple-negative breast cancer (TNBC) with PD-L1 combined positive score (CPS) <10: Safety, antitumor activity, and association between biomarkers and response
Cancer Research·2024
Author Correction: T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection
Nature Medicine·2024· 1 citedOpen Access
Advances in Therapies Targeting Inhibitory Checkpoint Receptors: TIGIT, LAG-3, and Beyond
Annual Review of Cancer Biology·2023· 4 citedOpen Access
Supplementary Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors
2023Open Access
Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors
2023Open Access
Supplementary Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors
2023Open Access
Supplementary Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors
2023Open Access
Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors
2023Open Access
Supplementary Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors
2023Open Access
Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
Journal of Clinical Oncology·2023· 9 cited
Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy
Journal for ImmunoTherapy of Cancer·2022· 16 citedOpen Access
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies
Cancer Immunology Immunotherapy·2022· 31 citedOpen Access
Introducing a new reporter gene, membrane-anchored Cypridina luciferase, for multiplex bioluminescence imaging
Molecular Therapy — Oncolytics·2021· 15 citedOpen Access
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors
Clinical Cancer Research·2020· 52 citedOpen Access
794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors
2020· 4 citedOpen Access
First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors
Cancer·2020· 65 citedOpen Access
O83 Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
Oral Presentations·2020· 6 citedOpen Access
Anticuerpos y conjugados inmunitarios terapeúticos
Dialnet (Universidad de la Rioja)·2020
page 1 of 3Next →

Frequent Co-authors

Elliot Chartash(15), Vladimir Ponomarev(10), Richard Wnek(10), С. Р. Варфоломеева(10), Georgina V. Long(9), Р. Т. Абдуллаев(9), Larissa Shenker(8), Yury Likar(7), Kyriakos P. Papadopoulos(7), Karen A. Autio(7), Talia Golan(7), Nai‐Kong V. Cheung(6), Hedvig Hricak(6), Qiusheng Chen(6), Т. В. Шаманская(6), Michel Sadelain(5), Malgorzata Olszewska(4), Shangde Cai(4), Juan Zurita(4), Martin Wermke(4)